Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.

Trial Profile

Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Prostate cancer vaccine (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Sep 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 19 Apr 2009 Status changed from active, no longer recruiting to completed, as reported in bstract number 729 presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR), held in Denver, Colorado, USA in April 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top